Researchers from the University of Toronto (UT) have recently discovered a potential way to detect a genetic predisposition for Amyotrophic Lateral Sclerosis (ALS), before the debilitating symptoms of the disease begin. The study, entitled, “Jump from Pre-mutation to Pathologic Expansion in C9orf72,” was published in the…
Study Findings May Lead To Future Genetic Test For ALS
Q Therapeutics, Inc., a clinical-stage company committed to find new therapies that might address central nervous system (CNS) diseases, has recently announced that the United States Food and Drug Administration (FDA) has cleared the company’s Investigational New Drug Application (IND) so that Q-Cells’ Phase 1/2a trials can be initiated in patients with amyotrophic lateral sclerosis (ALS). ALS,…
News
Q Therapeutics Announces FDA Clearance of Its Stem Cell Therapy Q-Cells for Human Trials in ALS
Q Therapeutics, Inc., a company focused on adult stem cell therapies for disorders of the central nervous system, recently announced that its product Q-Cells® has received Investigational New Drug (IND) clearance by the U.S. Food and Drug Administration (FDA) for the start of Phase 1/2a clinical trials in…
Sigma-Aldrich Corporation recently announced it has established an agreement with XCell Science to launch genetically engineered human neural differentiated cells and the corresponding culture media to advance research in the neurological diseases field. Together with the product portfolio of Sigma-Aldrich, these new products offer unique tools relevant for the…
In a recent study published in the journal BMC Neurology researchers found that despite the lack of a curative therapy, Amyotrophic Lateral Sclerosis carergivers (including specialized physicians as well as nursing and familial caregivers) can substantially contribute to the maintenance of quality of life (QoL) at the…
According to a recent study published in the journal JAMA Neurology, type 2 diabetes is associated with a diminished risk of amyotrophic lateral sclerosis (ALS). The study revealed that the risk is directly associated with the age at diagnosis of diabetes and the age at diagnosis of…
In a new study entitled “Dietary Vitamin D3 Restriction Exacerbates Disease Pathophysiology in the Spinal Cord of the G93A Mouse Model of Amyotrophic Lateral Sclerosis,” researchers evaluated the effects of a Vitamin D dietary restriction in the pathogenesis of Amyotrophic lateral sclerosis. The study was performed with…
Dr. Erik P. Pioro at the Neurological Institute, Cleveland Clinic in Ohio conducted a review on clinical data supporting treatment with dextromethorphan (DM) hydrobromide combined with quinidine sulfate (Q) for a disorder called pseudobulbar affect (PBA) that can occur in amyotrophic lateral sclerosis (ALS) patients. The study was published…
A neural prosthetic device surgically implanted in Erik G. Sorto, 34, left quadriplegic by gunshot wound 13 years ago, has enabled the single father of two to now move a robotic arm via only thought input. This major breakthrough is the outcome of a clinical collaboration between The California Institute…
A new study conducted by researchers at the Universidad Nacional Autónoma de México in Mexico recently revealed new insights into the mechanisms underlying motor neuron degeneration, offering potential new treatment strategies for amyotrophic lateral sclerosis (ALS). The study is entitled “Degeneration of spinal motor neurons by…
Recent Posts
- New funding backs commercial readiness efforts for ALS therapy
- US lawmakers reintroduce bill to improve access to treatment for ALS
- An emotional dance performance mirrored my life with ALS
- Expanded access program for ALS drug MN-166 at 50% enrollment
- US clinical trials lack diverse representation of ALS patients